Considerable on MSN
GSK buys Rapt in $2.2B deal
GSK agreed to acquire Rapt Therapeutics for $2.2 billion on Tuesday, a move that ...
GSK’s respiratory drug lineup spans a newly approved product for chronic obstructive pulmonary disease as well as therapeutic candidates in various stages of clinical development for treating this ...
By Pushkala Aripaka and Bhanvi Satija Jan 20 (Reuters) - Britain's GSK has agreed to buy RAPT Therapeutics for $2.2 billion, ...
You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in your inbox every ...
With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...
Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...
The growing scourge of food allergies drove U.K. heavyweight GSK to announce a $2.2 billion deal on Tuesday.
GSK acquires Rapt Therapeutics for $2.2B. Stock surges 65% as pharma giant gains access to phase 2b food allergy treatment ...
Risvutatug rezetecan received orphan drug designation for SCLC, supported by early clinical findings showing durable responses in ES-SCLC. Orphan drug designation incentivizes development for rare ...
Add Yahoo as a preferred source to see more of our stories on Google. GSK said that the drug met its primary endpoint GSK’s triple-action investigational antisense oligonucleotide (ASO) candidate has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results